Chiesi sets up new rare diseases unit

The family-controlled Italian drugmaker Chiesi Group today launched a new business unit dedicated to research and new product development for rare and ultra-rare diseases.

The unit, Chiesi Global Rare Diseases (GRD), will be based in Boston, USA, and initially focus on bringing innovative therapies to people living with lysosomal storage disorders (LSDs) and rare hematology and ophthalmology disorders.

“Chiesi has a long history of success in discovering, developing and commercializing innovative therapies to address unmet needs for people living with rare diseases. With the Chiesi Global Rare Diseases unit, we are taking this to an entirely new level – rededicating and strengthening our efforts to support individuals and families affected by rare diseases all around the world,” said Giamcomo Chiesi, head of Chiesi Global Rare Disease.

“We are officially launching the division in advance of the WORLDSymposium, one of the most important annual meetings focused on rare diseases. During the meeting, we look forward to connecting with many members of the lysosomal storage disorder and broader rare disease communities to outline our hopes and goals for the division and identify opportunities for us to collaborate in research and patient advocacy,” he added.